Closed
The Marked Chart Wire · Business
Regeneron
Investors anticipate Regeneron to report third quarter profit of $16.19 per share and sales of $4.56 billion. Recent upgrades follow a prolonged supply contract with BARDA for the drug Inmazeb.
Prices from Before the open · based on Thu close · Opens 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Nigeria Oil
TotalEnergies signed a farm-out agreement to transfer 40 percent of its interest in Nigeria's OPL257 to SAPETRO. The company will retain a 50 percent operated stake, with Conoil holding the remaining 10 percent.
Sanofi
The pharmaceutical company raised its annual profit target, citing solid performance from its top-selling drug Dupixent.
AstraZeneca
AstraZeneca reported third-quarter profit of $3.12 billion, up from $2.53 billion a year earlier. The company reiterated its full-year 2026 revenue and core EPS targets.
TotalEnergies
TotalEnergies indicated it expects 2026 cash flow to exceed $42 billion. The company also approved $2.5 billion in quarterly share buybacks extending into Q1 2027.
Sanofi
Sanofi reported third-quarter business EPS of 3.55 euros, a 22 percent increase. Sales reached 14.44 billion euros, up 16.2 percent, or 14.3 percent at constant exchange rates.
Sanofi
The pharmaceutical company reported quarterly results that exceeded analyst forecasts for both revenue and profit. Sanofi subsequently raised its guidance for the full fiscal year 2026.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.